CN106795154B - 用于治疗癌症的异喹啉酮衍生物 - Google Patents

用于治疗癌症的异喹啉酮衍生物 Download PDF

Info

Publication number
CN106795154B
CN106795154B CN201580047253.7A CN201580047253A CN106795154B CN 106795154 B CN106795154 B CN 106795154B CN 201580047253 A CN201580047253 A CN 201580047253A CN 106795154 B CN106795154 B CN 106795154B
Authority
CN
China
Prior art keywords
compound
added
halogen
alkyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580047253.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN106795154A (zh
Inventor
E·B·卡卢
P·施米特
A·克鲁琴斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of CN106795154A publication Critical patent/CN106795154A/zh
Application granted granted Critical
Publication of CN106795154B publication Critical patent/CN106795154B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201580047253.7A 2014-09-02 2015-09-02 用于治疗癌症的异喹啉酮衍生物 Expired - Fee Related CN106795154B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14306352 2014-09-02
EP14306352.7 2014-09-02
PCT/EP2015/070082 WO2016034642A1 (en) 2014-09-02 2015-09-02 Isoquinolinone derivatives useful in the treatment of cancer

Publications (2)

Publication Number Publication Date
CN106795154A CN106795154A (zh) 2017-05-31
CN106795154B true CN106795154B (zh) 2019-07-05

Family

ID=51494243

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580047253.7A Expired - Fee Related CN106795154B (zh) 2014-09-02 2015-09-02 用于治疗癌症的异喹啉酮衍生物

Country Status (8)

Country Link
US (1) US9944641B2 (enExample)
EP (1) EP3189051A1 (enExample)
JP (1) JP2017525734A (enExample)
CN (1) CN106795154B (enExample)
BR (1) BR112017003651A2 (enExample)
MX (1) MX2017002544A (enExample)
RU (1) RU2690853C2 (enExample)
WO (1) WO2016034642A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3481826T3 (da) * 2016-07-08 2022-01-10 Rigel Pharmaceuticals Inc Tyrosinkinaseinhibitorer
CN106699608A (zh) * 2016-12-26 2017-05-24 常州大学 一种含有强吸电子基团的苯胍及其盐的制备方法
CN111683976B (zh) 2018-02-05 2022-11-18 生物辐射实验室股份有限公司 具有阴离子交换-疏水混合模式配体的色谱树脂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013041539A1 (en) * 2011-09-20 2013-03-28 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
WO2013126656A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2783B1 (en) * 2005-09-30 2014-03-15 نوفارتيس ايه جي Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
US9029391B2 (en) 2011-01-24 2015-05-12 Viiv Healthcare Uk Limited Isoquinoline compounds and methods for treating HIV
EP2807166B1 (en) * 2012-01-23 2016-04-06 Boehringer Ingelheim International GmbH 5,8-dihydro-6h-pyrazolo[3,4-h]quinazolines as igf-1r/ir inhibitors
EP2970317A4 (en) * 2013-03-15 2016-11-02 Dana Farber Cancer Inst Inc PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013041539A1 (en) * 2011-09-20 2013-03-28 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
WO2013126656A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Synthesis of substituted diazino[c]quinolin-5(6H)-ones, diazino[c]isoquinolin-6(5H)-ones, diazino[c]naphthyridin-6(5H)-ones and diazino[c]naphthyridin-5(6H)-ones;Nathalie Fresneau, et al.;《Tetrahedron》;20130428;第69卷(第26期);5393-5400 *

Also Published As

Publication number Publication date
BR112017003651A2 (pt) 2017-12-05
CN106795154A (zh) 2017-05-31
US20170240544A1 (en) 2017-08-24
RU2017108909A (ru) 2018-10-03
JP2017525734A (ja) 2017-09-07
US9944641B2 (en) 2018-04-17
RU2017108909A3 (enExample) 2018-12-13
RU2690853C2 (ru) 2019-06-06
MX2017002544A (es) 2017-07-19
EP3189051A1 (en) 2017-07-12
WO2016034642A1 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
CN115677702B (zh) 三并环化合物及其药物组合物和应用
ES2398299T3 (es) Indoles como moduladores de 5-HT6
Ma et al. Design, synthesis, biological evaluation and preliminary mechanism study of novel benzothiazole derivatives bearing indole-based moiety as potent antitumor agents
CA3032795C (en) Imidazopyridinamine phenyl derivative and use thereof
CN105503827B (zh) Egfr抑制剂及其制备方法和用途
CN110546145B (zh) 一种氮杂芳基衍生物、其制备方法和在药学上的应用
CN105968115B (zh) 喹啉类化合物、其制备方法、中间体、药物组合物和应用
CN111343988A (zh) 作为ehmt2抑制剂的胺取代的杂环化合物及其衍生物
PT2552909E (pt) Derivados de 4-aminopirimidina e sua utilização como antagonistas de recetor de adenosina a2a
BR112015017963B1 (pt) Composto de fenil amino pirimidina deuterado, método para preparar a composição farmacêutica, composição farmacêutica e uso do composto
JP2019533650A (ja) Ｅｈｍｔ２阻害剤としての置換された融合二環式または三環式複素環化合物
WO2015060373A1 (ja) キナゾリノンおよびイソキノリノン誘導体
WO2020219448A1 (en) Naphthyridine derivatives as prc2 inhibitors
Yang et al. Design, synthesis and biological evaluation of dihydroquinoxalinone derivatives as BRD4 inhibitors
WO2025087267A1 (zh) 一种含有噻唑基的哌啶并嘧啶类衍生物、其制备方法及其医药上的应用
TW202444700A (zh) 作為sarm1抑制劑之經取代1h-吡唑-4-甲醯胺化物
RU2690853C2 (ru) Производные изохинолинона, полезные для лечения рака
JP2022547200A (ja) 三環系構造を有する芳香複素環式化合物、およびその調製方法と適用
WO2020057669A1 (zh) 一类具有激酶抑制活性的芳香杂环类化合物
DK3189060T3 (en) DERIVATIVES OF MACROCYCLIC N-ARYL-2-AMINO-4-ARYL-PYRIMIDINE POLYETHERS AS FTL3 AND JAK INHIBITORS
JP7729632B2 (ja) 新規三環芳香族複素環化合物、ならびにその調製方法、医薬組成物および適用
CN112759588B (zh) 苯并五元杂环胺类衍生物及其用途
CN105705499B (zh) 用于制备化合物的方法
HK1233639A1 (en) Isoquinolinone derivatives useful in the treatment of cancer
WO2020200154A1 (zh) 一类噻吩并氮杂环类化合物、制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1233639

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190705

Termination date: 20210902

CF01 Termination of patent right due to non-payment of annual fee
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1233639

Country of ref document: HK